
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新数据
US$37.305
−US$0.125 · -0.33%
Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions. While serving a global clientele, its primary market for livestock products is the United States. The company's operations are divided into three main business segments: Animal Health, Mineral Nutrition, and Performance Products. Phibro develops, manufactures, and markets products tailored for various food-producing animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its Animal Health offerings encompass a broad range of pharmaceutical and biological products. These include antimicrobials (both chemical and biological agents) designed to prevent and treat bacterial ailments; anticoccidials, primarily used to control and prevent coccidiosis in poultry and cattle; anthelmintics for combating parasitic intestinal worm infestations; and specific anti-bloat treatments for cattle grazing on legume or wheat pastures. Additionally, the company provides specialized nutritional supplements engineered to enhance animal health and performance, alongside vaccines predominantly for the poultry and swine industries to protect against diseases. The Mineral Nutrition segment focuses on the creation and distribution of various trace mineral formulations and concentrates, featuring elements such as zinc, manganese, copper, iron, and other vital compounds. Furthermore, under its Performance Products segment, Phibro supplies an assortment of specialty ingredients that find application in diverse industries, including personal care, industrial chemicals, and chemical catalysts. Phibro's animal health and mineral nutrition products reach customers through a multi-channel distribution network, including its own local sales offices, direct sales to integrated poultry, swine, and cattle operations, and through commercial animal feed producers, wholesalers, and distributors. The company boasts an extensive international presence, conducting business across the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific region. Initially known as Philipp Brothers Chemicals, Inc., the company adopted the name Phibro Animal Health Corporation in July 2003. It was officially incorporated in 2014 and maintains its corporate headquarters in Teaneck, New Jersey.
常规交易时段
US$37.305
−US$0.125 · -0.33%
盘中时间采用ET。市场数据可能有所延迟。
Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions. While serving a global clientele, its primary market for livestock products is the United States. The company's operations are divided into three main business segments: Animal Health, Mineral Nutrition, and Performance Products. Phibro develops, manufactures, and markets products tailored for various food-producing animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its Animal Health offerings encompass a broad range of pharmaceutical and biological products. These include antimicrobials (both chemical and biological agents) designed to prevent and treat bacterial ailments; anticoccidials, primarily used to control and prevent coccidiosis in poultry and cattle; anthelmintics for combating parasitic intestinal worm infestations; and specific anti-bloat treatments for cattle grazing on legume or wheat pastures. Additionally, the company provides specialized nutritional supplements engineered to enhance animal health and performance, alongside vaccines predominantly for the poultry and swine industries to protect against diseases. The Mineral Nutrition segment focuses on the creation and distribution of various trace mineral formulations and concentrates, featuring elements such as zinc, manganese, copper, iron, and other vital compounds. Furthermore, under its Performance Products segment, Phibro supplies an assortment of specialty ingredients that find application in diverse industries, including personal care, industrial chemicals, and chemical catalysts. Phibro's animal health and mineral nutrition products reach customers through a multi-channel distribution network, including its own local sales offices, direct sales to integrated poultry, swine, and cattle operations, and through commercial animal feed producers, wholesalers, and distributors. The company boasts an extensive international presence, conducting business across the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific region. Initially known as Philipp Brothers Chemicals, Inc., the company adopted the name Phibro Animal Health Corporation in July 2003. It was officially incorporated in 2014 and maintains its corporate headquarters in Teaneck, New Jersey.
日内区间
当前US$37.305
52周区间
当前US$37.305
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
87
深度低估
情绪
41
多空交织
风险
57
风险偏高
动量
27
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions. While serving a global clientele, its primary market for livestock products is the United States. The company's operations are divided into three main business segments: Animal Health, Mineral Nutrition, and Performance Products. Phibro develops, manufactures, and markets products tailored for various food-producing animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its Animal Health offerings encompass a broad range of pharmaceutical and biological products. These include antimicrobials (both chemical and biological agents) designed to prevent and treat bacterial ailments; anticoccidials, primarily used to control and prevent coccidiosis in poultry and cattle; anthelmintics for combating parasitic intestinal worm infestations; and specific anti-bloat treatments for cattle grazing on legume or wheat pastures. Additionally, the company provides specialized nutritional supplements engineered to enhance animal health and performance, alongside vaccines predominantly for the poultry and swine industries to protect against diseases. The Mineral Nutrition segment focuses on the creation and distribution of various trace mineral formulations and concentrates, featuring elements such as zinc, manganese, copper, iron, and other vital compounds. Furthermore, under its Performance Products segment, Phibro supplies an assortment of specialty ingredients that find application in diverse industries, including personal care, industrial chemicals, and chemical catalysts. Phibro's animal health and mineral nutrition products reach customers through a multi-channel distribution network, including its own local sales offices, direct sales to integrated poultry, swine, and cattle operations, and through commercial animal feed producers, wholesalers, and distributors. The company boasts an extensive international presence, conducting business across the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific region. Initially known as Philipp Brothers Chemicals, Inc., the company adopted the name Phibro Animal Health Corporation in July 2003. It was officially incorporated in 2014 and maintains its corporate headquarters in Teaneck, New Jersey.
日内区间
当前US$37.305
52周区间
当前US$37.305
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2026财年 | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|---|
| 营收 | 15.18亿 USD | 12.96亿 USD | 10.18亿 USD | 9.78亿 USD | 9.42亿 USD |
| 销货成本 | 10.06亿 USD | 8.96亿 USD | 7.05亿 USD | 6.8亿 USD | 6.57亿 USD |
| 毛利 | 5.12亿 USD | 4亿 USD | 3.13亿 USD | 2.98亿 USD | 2.85亿 USD |
| 销售、一般及管理费用 | 3.13亿 USD | 2.89亿 USD | 2.6亿 USD | 2.26亿 USD | 2.06亿 USD |
| 营业费用 | 3.13亿 USD | 2.89亿 USD | 2.6亿 USD | 2.26亿 USD | 2.06亿 USD |
| 利息收入 | 145.9万 USD | 262.2万 USD | 447.4万 USD | 335.5万 USD | 81.6万 USD |
| 利息支出 | 4760.4万 USD | 3324.9万 USD | 2197万 USD | 1794.9万 USD | 1210.1万 USD |
| 折旧和摊销 | 5151.4万 USD | 4560.5万 USD | 3617.8万 USD | 3401.2万 USD | 3270.5万 USD |
| 营业利润 | 1.98亿 USD | 1.1亿 USD | 5331.5万 USD | 7184.7万 USD | 7898.6万 USD |
| 净利润 | 9972万 USD | 4826.4万 USD | 241.6万 USD | 3260.6万 USD | 4917.5万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$28.00
下跌空间 24.94%年度分割调整后的每股现金分配。
US$0.48
2025年(完整年度)0.0% 自从 2021
2026年(部分年度):US$0.36
US$0.48
2,021
US$0.48
2,022
US$0.48
2,023
US$0.48
2,024
US$0.48
2,025
US$0.36
2,026*
* 在现有股息历史记录中,该日历年仅包含部分期间。
| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2026年9月2日 | US$0.12Quarterly | 2026年9月2日 | 2026年9月23日 |
股息 | 2026年6月3日 | US$0.12Quarterly | 2026年6月3日 | 2026年6月24日 |
股息 | 2026年3月4日 | US$0.12Quarterly | 2026年3月4日 | 2026年3月25日 |
股息 | 2025年11月26日 | US$0.12Quarterly | 2025年11月26日 | 2025年12月17日 |
股息 | 2025年9月3日 | US$0.12Quarterly | 2025年9月3日 | 2025年9月24日 |
股息 | 2025年6月4日 | US$0.12Quarterly | 2025年6月4日 | 2025年6月25日 |
除息 2026年9月2日
US$0.12
Quarterly
2026年9月2日登记 · 支付日 2026年9月23日
除息 2026年6月3日
US$0.12
Quarterly
2026年6月3日登记 · 支付日 2026年6月24日
除息 2026年3月4日
US$0.12
Quarterly
2026年3月4日登记 · 支付日 2026年3月25日
除息 2025年11月26日
US$0.12
Quarterly
2025年11月26日登记 · 支付日 2025年12月17日
除息 2025年9月3日
US$0.12
Quarterly
2025年9月3日登记 · 支付日 2025年9月24日
除息 2025年6月4日
US$0.12
Quarterly
2025年6月4日登记 · 支付日 2025年6月25日
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2489.43万0.00%2.3万亿 USD0.03%US$380.85-0.19%
iShares Russell 2000 ETFIWM2044.39万0.03%787.4亿 USD0.19%US$276.29-0.58%
Vanguard Extended Market ETFVXF925.37万0.01%954亿 USD0.05%US$232.09-0.61%
iShares Russell 2000 Growth ETFIWO730.76万0.05%139.17亿 USD0.24%US$350.66-0.86%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM721.9万0.05%157.12亿 USD0.03%US$53.275-0.27%
Dimensional - US Small Cap ETFDFAS621.7万0.02%338.04亿 USD0.31%US$78.04-0.17%
State Street SPDR S&P Pharmaceuticals ETFXPH583.52万1.24%4.69亿 USD0.35%US$62.705-2.04%
State Street SPDR S&P 600 Small Cap Growth ETFSLYG464.06万0.10%48.09亿 USD0.15%US$107.7-0.58%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWO
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM
Dimensional - US Small Cap ETFDFAS
State Street SPDR S&P Pharmaceuticals ETFXPH
State Street SPDR S&P 600 Small Cap Growth ETFSLYGAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。